In Phase C, members will acquire ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Members will get treatment till ailment progression or perhaps the members are unable to tolerate the study drugs. For all flow cytometry experiments, 10,000 cells per replicate were analyzed, and three https://abbv-744combinationtherap68912.livebloggs.com/38378206/abbv-744-clinical-trial-phase-2-data-things-to-know-before-you-buy